- Summary
- Price Reports
- Price History
- Add To Your Stocklist
- View your Stocklist
- Basic Chart
- Interactive Chart
- Headlines (24h)
- Company Snapshot
- Summary Reports
- Free Annual Report
- Estimate Snapshot
- Estimate Report
- Mobile Quote
- Real-Time Quote
- Streaming Quote
|
Transcept Pharmaceuticals | Company Snapshot
-
![]()
-
-
-
Vol:
-
Last Trade:
|
TRANSCEPT PHARMACEUTICALS INC.
NOVACEA, INC. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has two product candidates, including Asentar, which has been in a Phase three clinical trial for androgen-independent prostate cancer, and in a Phase two trial for advanced pancreatic cancer. Novacea's second product candidate, AQ4N, is a hypoxia-activated prodrug that is currently in a Phase 1b/2a clinical trial in glioblastoma multiforme.
|
|
| Symbol: |
TSPT |
| Exchange(s): |
Nasdaq Stock Market |
| Industry: |
Consumer Products (Biotechnology & Pharmaceuticals) |
| 5-Star Rating: |
 |
|
ANNUAL FINANCIALS
|
|
|
Dec 31, 2008
12 Months
us$
|
Dec 31, 2007
12 Months
us$
|
Dec 31, 2006
12 Months
us$
|
3Yr.
Growth
% Change
|
|
Total Revenue ($000)
|
60,620
|
16,680
|
370
|
N/A
|
|
Earnings before Interest & Tax ($000)
|
34,820
|
-32,530
|
-29,620
|
N/A
|
|
Profit/Loss ($000)
|
34,820
|
-32,530
|
-29,620
|
N/A
|
|
Earnings per Share
|
-7.03
|
-6.75
|
-9.90
|
N/A
|
|
Total Assets ($000)
|
86,810
|
109,820
|
66,060
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
0.00
|
|
|
Return on Com. Equity
|
53.66
|
-61.63
|
N/A
|
|
|
Employees
|
N/A
|
N/A
|
N/A
|
|
|
|
|
|
Trailing 12 Month Results
|
|
|
12 Months ended
Dec 31, 2009,us$
|
12 Months ended
Dec 31, 2008,us$
|
%Change
|
|
Total Revenue ($000)
|
N/A
|
60,640
|
N/A
|
|
Profit/Loss ($000)
|
N/A
|
32,950
|
N/A
|
|
Earnings per Share
|
N/A
|
5.62
|
N/A
|
|
Dividends Per Share
|
0.00
|
0.00
|
|
Number of Shares
|
13,370,000
|
5,180,000
|
|
|
|
|
|
COMPANY INFORMATION
|
| Key Personnel |
| CEO: John P. Walker, Chmn.; C.E.O. |
| CFO: Edward C. Albini, V.P.; C.F.O.; Princ. Acctg. Of |
| |
| Contact Information |
| Address: |
400 Oyster Point Boulevard,
Suite 200,
South San Francisco,
CA,
94080 |
Phone: |
650-228-1800 |
| Web Address: |
www.novacea.com |
| |
| |
| Incorporation:
| United States |
| |
|
Securities:
|
TSPT-Q
|
|
| |
|
|
| |
|
|
Financial data is provided by Zacks Investment Research.
| |
All information on this site is compiled by CTVglobemedia Publishing Inc. from reliable industry sources. While all efforts are made to ensure the accuracy of the information, CTVglobemedia Publishing Inc. and its related entities assume no liability for incorrect, incomplete, or missing information from this site. Past performance is not necessarily indicative of future performance. Prior to making any investment decision, consult with a qualified investment advisor.
Copyright © 2010 CTVglobemedia Publishing Inc. All rights reserved.
|
|
|
